DK200000677A - Fabrikerede artikler - Google Patents

Fabrikerede artikler Download PDF

Info

Publication number
DK200000677A
DK200000677A DK200000677A DKPA200000677A DK200000677A DK 200000677 A DK200000677 A DK 200000677A DK 200000677 A DK200000677 A DK 200000677A DK PA200000677 A DKPA200000677 A DK PA200000677A DK 200000677 A DK200000677 A DK 200000677A
Authority
DK
Denmark
Prior art keywords
treatment
sexual dysfunction
pde5
pde5 inhibitor
patient
Prior art date
Application number
DK200000677A
Other languages
English (en)
Inventor
Jeffrey Thomas Emmick
Ferguson Kenneth Michael
William Ernest Pullman
John Steven Whitaker
Original Assignee
Lilly Icos Llc A Delaware Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200000677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc A Delaware Ltd filed Critical Lilly Icos Llc A Delaware Ltd
Publication of DK200000677A publication Critical patent/DK200000677A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Glass Compositions (AREA)

Description

Patentkrav. 1. Fabrikeret artikel til medicinsk brug ved behandling af mennesker omfattende: (a) en oral dosisform omfattende ca. 1 til ca. 20 mg af en selektiv PDE5-inhibitor, som besidder (i) mindst eh 100 ganges forskel mellem IC50-værdierne for inhibering af PDE5 i forhold til PDE6, (ii) mindst en 1000 ganges forskel imellem IC5o-værdieme for inhibering af PDE5 i forhold til PDE1c, (iii) en IC50 mindre end 10 nM, og (iv) tilstrækkelig biotilgængelighed til at være effektiv i orale enhedsdoser på ca. 1 til ca. 20 mg; (b) et pakkeindlæg, som angiver, at PDE5-inhibitoren er nyttig ved behandling af seksuel dysfunktion i en patient, som har behov derfor, og at det er fri for kontraindikationer i forbindelse med indgivelse af organiske nitrater; og (c) en beholder. 2. Fabrikeret artikel til medicinsk brug ved behandling af mennesker omfattende: (a) en oral dosisform omfattende ca. 1 til ca. 20 mg af selektiv PDE5-inhibitor , som besidder (i) en mindst 100 ganges forskel imellem IC50-værdierne for inhibering af PDE5 i forhold til PDE6, (ii) en mindst 1000 ganges forskel imellem IC50-værdierne for inhibering af PDE5 i forhold til PDE1c, (iii) en IC50 mindre end 10 nM, og (iv) en tilstrækkelig biotilgængelighed til at være orale enhedsdoser på ca. 1 til ca. 20 mg (b) et pakkeindlæg, som angiver, at PDE5-inhibitoren er nyttig ved behandlingen af seksuel dysfunktion i en patient, som har behov derfor, og som anvender et organisk nitrat; og (c) en beholder. 3. Fabrikeret artikel til medicinsk brug ved behandling af mennesker omfattende: (a) en oral dosisform omfattnede ca. 1 til ca. 20 mg af en selektiv PDE5 inhinbitor, som besidder (i) mindst en 100 ganges forskel imellem IC50-værdierne for inhibering af PDE5 i forhold til PDE6, (ii) mindst en 1000 ganges forskel imellem IC50-værdierne for inhibering af PDE5 i forhold til PDE1c, (iii) en IC50 mindre end 10 nM, og (iv) en tilstrækkelig biotilgængelighed til at være effektiv i orale enhedsdoser på ca. 1 til ca. 20 mg; (b) et pakkeindlæg, der angiver, at PDE5-inhibitoren er nyttig ved behandlingen af seksuel dysfunktion i en patient, som har behov derfor, og som lider af en tilstand udvalgt fra gruppen bestående af en nethindesygdom, tilbøjelighed til rødmen, tilbøjelighed til synsforstyrrelser, klasse 1 kongestiv hjertestop, et myo-kardieinfarkt 90 dage eller mere før igangsættelsen af den seksuelle dysfunktionbehandling, og kombinationer af disse; og (c) en beholder. 4. Artikel ifølge krav 3, hvori nethindesygdommen er diabetisk retinopati eller Retinitis pigmentosa. 5. Artikel ifølge krav 3, hvori omtalte pakkeindlæg beskriver, at rødmen forekommer hos mindre end 2% af behandlede patienter. 6. Artikel ifølge krav 1 til 5, hvori den orale dosisform omfatter ca. 5 mg, ca. 10 mg eller ca. 20 mg af en selektiv PDE5-inhibitor. 7. Artikel ifølge krav 1 til 6, hvori pakkeindlægget beskriver en maksimal dosis af den selektive PDE5-inhibitor på ca. 20 mg pr. 24 timer. 8. Artikel ifølge krav 1 til 7, hvori den selektive PDE5-inhibitor har strukturen
Figure DK200000677AD00051
9. Fabrikeret artikel som i al væsentlighed tidligere beskrevet i denne specifikation. 10. Anvendelse af en selektiv PDE5-inhibitor til fremstilling af et medikament til behandling af seksuel dysfunktion i en patient, der behandles med et organisk nitrat. 11. Anvendelse af en selektiv PDE5-inhibitor til fremstilling af et medikament til behandling af seksuel dysfunktion i en patient, der har tilbøjelighed til synsforstyrrelser, tilbøjelighed til rødmen, lider af en nethindesygdom, lider af klasse 1 kongestiv hjertestop, eller som led af myocardieinfarkt 90 dage eller mere før igangsættelsen af behandlingen af seksuel dysfunktion. 12. Farmaceutisk formulering tilpasset til behandlingen af seksuel dysfunktion i en patient, der behandles med et organisk nitrat, der som aktiv ingrediens omfatter en selektiv PDE5-inhibitor, således som de tidligere heri beskrevne. 13. Farmaceutisk formulering tilpasset til behandlingen af seksuel dysfunktion i en patient, der har tilbøjelighed til rødmen, der som aktiv ingrediens omfatter en selektiv PDE5-inhibitor, således som de tidligere heri beskrevne. 14. Farmaceutisk formulering tilpasset til behandlingen af seksuel dysfunktion i en patient, der lider af en nethindesygdom, der som aktiv ingrediens omfatter en selektiv PDE5-inhibitor, således som de tidligere heri beskrevne. 15. Farmaceutisk formulering tilpasset til behandlingen af seksuel dysfunktion i en patient, der lider af klasse 1 kongestiv hjertestop eller led af et myocardieinfarkt 90 dage eller mere før påbegyndelsen af behandlingen af seksuel dysfunktion, der som aktiv ingrediens omfatter en selektiv PDE5-inhibitor som tidligere heri beskrevet. 16. Fremgangsmåde til behandling af seksuel dysfunktion omfattende anvendelse af en fabrikeret artikel ifølge krav 1 til 8.
DK200000677A 1999-04-30 2000-04-26 Fabrikerede artikler DK200000677A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
DK200000677A true DK200000677A (da) 2000-10-31

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00926367T DK1173181T6 (da) 1999-04-30 2000-04-26 Sammensætning omfattende inhibitorer for phosphodiesterase til behandling af seksuel dysfunktion
DK200000677A DK200000677A (da) 1999-04-30 2000-04-26 Fabrikerede artikler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00926367T DK1173181T6 (da) 1999-04-30 2000-04-26 Sammensætning omfattende inhibitorer for phosphodiesterase til behandling af seksuel dysfunktion

Country Status (47)

Country Link
EP (2) EP1415652A3 (da)
JP (2) JP2000336043A (da)
KR (2) KR100577057B1 (da)
CN (2) CN1196487C (da)
AT (1) ATE251908T1 (da)
AU (3) AU3012900A (da)
BE (1) BE1012957A5 (da)
BR (2) BR0003046A (da)
CA (2) CA2371684C (da)
CH (2) CH1173181H1 (da)
CO (1) CO5170493A1 (da)
CZ (1) CZ296534B6 (da)
DE (3) DE20007861U1 (da)
DK (2) DK1173181T6 (da)
DZ (1) DZ3171A1 (da)
EA (2) EA200000355A3 (da)
ES (2) ES2187234A1 (da)
FI (1) FI20000976A7 (da)
FR (1) FR2795646B1 (da)
GB (1) GB2351663A (da)
GR (1) GR1003575B (da)
HK (1) HK1041204B (da)
HR (2) HRP20010778B1 (da)
HU (2) HUP0001632A3 (da)
ID (1) ID25704A (da)
IE (1) IE20000315A1 (da)
IL (3) IL135817A0 (da)
IT (1) ITMI20000922A1 (da)
LT (1) LT4758B (da)
LU (1) LU90569B1 (da)
LV (1) LV12560B (da)
MX (2) MXPA00003997A (da)
NL (1) NL1015027C2 (da)
NO (2) NO20002097L (da)
NZ (2) NZ514882A (da)
PE (1) PE20010071A1 (da)
PL (2) PL339897A1 (da)
PT (2) PT102457A (da)
SE (1) SE0001518L (da)
SG (1) SG98384A1 (da)
SI (2) SI20361A (da)
SK (1) SK285415B6 (da)
SV (1) SV2002000055A (da)
TR (1) TR200001132A3 (da)
UA (1) UA72248C2 (da)
WO (1) WO2000066099A2 (da)
ZA (2) ZA200002058B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72922C2 (uk) * 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
US20030153575A1 (en) * 2000-06-08 2003-08-14 Orme Mark W. Tetracyclic diketopiperazine compounds as pdev inhibitors
CA2423357C (en) 2000-08-02 2008-05-27 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
ES2286291T3 (es) 2001-06-05 2007-12-01 Lilly Icos Llc Compustos tetraciclicos como inhibidores de pde5.
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
MX2008012495A (es) * 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina.
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
KR102646431B1 (ko) 2017-09-29 2024-03-12 한미약품 주식회사 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
KR102894055B1 (ko) * 2018-02-07 2025-12-02 스마와 게엠베하 약학 제형, 약학 제형을 제조하기 위한 방법 및 이를 포함하는 의약

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
EE9800390A (et) 1996-05-10 1999-06-15 Icos Corporation Karboliini derivaadid
CA2288910C (en) * 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
CA2339630C (en) 1998-09-16 2006-05-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
AU4663100A (en) * 1999-04-30 2000-11-17 Lilly Icos Llc Treatment of female arousal disorder

Also Published As

Publication number Publication date
FR2795646B1 (fr) 2002-08-16
AU769946B2 (en) 2004-02-12
HUP0001632A2 (hu) 2001-05-28
DE10021266A1 (de) 2000-11-16
CA2307101C (en) 2003-01-28
GR1003575B (el) 2001-05-14
HUP0200912A3 (en) 2003-07-28
MXPA01010837A (es) 2002-11-07
ES2208317T3 (es) 2004-06-16
CN1292264A (zh) 2001-04-25
CN1384746A (zh) 2002-12-11
AU769946C (en) 2005-01-13
DZ3171A1 (da) 2000-11-09
MXPA00003997A (es) 2002-03-08
ITMI20000922A1 (it) 2001-10-26
ZA200108900B (en) 2003-03-26
NO322013B3 (no) 2017-11-06
LT2000035A (lt) 2000-11-27
NO20015275L (no) 2001-12-06
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
PL339897A1 (en) 2000-11-06
PT1173181E (pt) 2004-02-27
EA200000355A2 (ru) 2000-10-30
IL146098A0 (en) 2002-07-25
DE60005940T2 (de) 2004-07-29
SE0001518D0 (sv) 2000-04-26
TR200001132A2 (tr) 2001-01-22
UA72248C2 (en) 2005-02-15
AU4490800A (en) 2000-11-17
SG98384A1 (en) 2003-09-19
LT4758B (lt) 2001-02-26
NL1015027C2 (nl) 2001-02-14
KR100577057B1 (ko) 2006-05-10
HU0200912D0 (en) 2002-04-29
EA200000355A3 (ru) 2001-02-26
LU90569B1 (fr) 2002-02-27
KR20020008396A (ko) 2002-01-30
IE20000315A1 (en) 2001-03-07
IL135817A0 (en) 2001-05-20
HRP20010778B1 (en) 2005-04-30
GB2351663A (en) 2001-01-10
ES2187234A1 (es) 2003-05-16
CH1173181H1 (da) 2019-07-15
CO5170493A1 (es) 2002-06-27
PE20010071A1 (es) 2001-03-22
HRP20000243A2 (en) 2001-12-31
JP2002543116A (ja) 2002-12-17
JP4975214B2 (ja) 2012-07-11
SK285415B6 (sk) 2007-01-04
BR0010181A (pt) 2003-02-25
BE1012957A5 (fr) 2001-06-05
EA005416B1 (ru) 2005-02-24
HU0001632D0 (en) 2000-06-28
CA2371684C (en) 2007-10-23
BR0003046A (pt) 2002-07-23
NZ504163A (en) 2001-11-30
CZ20013879A3 (cs) 2002-04-17
PL197813B1 (pl) 2008-04-30
FR2795646A1 (fr) 2001-01-05
SV2002000055A (es) 2002-07-03
EP1173181B3 (en) 2015-03-25
CA2307101A1 (en) 2000-10-30
NO20002097L (no) 2001-10-26
IL146098A (en) 2007-06-03
KR20010020779A (ko) 2001-03-15
GB0010199D0 (en) 2000-06-14
AU3012900A (en) 2000-11-02
GR20000100153A (el) 2000-12-29
ZA200002058B (en) 2000-11-02
EP1173181A2 (en) 2002-01-23
NL1015027A1 (nl) 2000-10-31
DE60005940T3 (de) 2015-08-27
NO322013B1 (no) 2006-08-07
CA2371684A1 (en) 2000-11-09
ID25704A (id) 2000-11-02
JP2000336043A (ja) 2000-12-05
CH692478A5 (de) 2002-07-15
WO2000066099A3 (en) 2001-01-18
EP1173181B1 (en) 2003-10-15
ITMI20000922A0 (it) 2000-04-26
SI20361A (sl) 2001-04-30
SE0001518L (sv) 2000-10-31
LV12560B (en) 2001-04-20
EP1415652A3 (en) 2004-05-12
FI20000976L (fi) 2000-10-30
EA200101008A1 (ru) 2002-04-25
WO2000066099A2 (en) 2000-11-09
DE60005940D1 (de) 2003-11-20
HK1041204B (en) 2004-03-05
ES2208317T7 (es) 2015-09-15
PT102457A (pt) 2000-11-30
ATE251908T1 (de) 2003-11-15
HU230369B1 (hu) 2016-03-29
FI20000976A0 (fi) 2000-04-26
HUP0200912A2 (en) 2002-08-28
CN1196487C (zh) 2005-04-13
TR200001132A3 (tr) 2001-01-22
AU2004201988A1 (en) 2004-06-10
DK1173181T3 (da) 2004-02-16
SI1173181T1 (en) 2004-04-30
NZ514882A (en) 2003-08-29
EP1415652A2 (en) 2004-05-06
CZ296534B6 (cs) 2006-04-12
NO20002097D0 (no) 2000-04-25
HUP0001632A3 (en) 2001-12-28
PL352629A1 (en) 2003-08-25
FI20000976A7 (fi) 2000-10-30
DE20007861U1 (de) 2000-08-24
DK1173181T6 (da) 2015-04-27
SK15632001A3 (sk) 2002-02-05
NO20015275D0 (no) 2001-10-29
LV12560A (en) 2000-11-20

Similar Documents

Publication Publication Date Title
DK200000677A (da) Fabrikerede artikler
CA2208199C (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP0481675B1 (en) Preparation of medicaments for treating asthma using (S)-alpha-fluoromethyl histidine and esters thereof
IL197235A (en) Medical and product preparations containing ingredients that have pde5 inhibitor properties and their use in the manufacture of drugs
ZA200206758B (en) Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker dis-intoxication.
EP1274414B1 (en) Nasal administration of metoclopramide for the treatment of gastroparesis
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
EP0813873B1 (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
AU779761B2 (en) Medicament for treatment of neuropathies
HRP20010741A2 (en) Use of osanetant in the production of medicaments used to treat mood disorders
HUT57584A (en) Process for producing pharmaceutical compositions suitable for treating drug addiction and comprising dopamin-autoreceptor agonists
WO2010020789A2 (en) Medicament and treatment for infections
CA3058996A1 (en) Cytisinicline in the treatment of smoking addiction for refractory subjects
Patil et al. Dissolution Profile of Various (Three) Marketed Brands of Metformin Hydrochloride
Joseph et al. Recent therapeutic advances in leprosy and their implications in clinical practice
CZ238692A3 (en) The use of calcium antagonists from the group of 1,4-dihydropyridines for the preparation of medicaments
MX2014000455A (es) Terapia de combinacion para esclerosis lateral amiotrofica.
HK1006081B (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TH33473B (th) ไพราโซโลไพริดีนที่ถูกแทนที่ด้วยคาร์บาเมต
MXPA00009614A (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment